The Bet Behind Merck's Rally
If you only glanced at Merck’s headlines this year, the picture looked messy. Revenue in the latest reported quarter was higher than a year earlier, yet net income and margin both moved the wrong way. Holding Merck over the past year would have returned 62.8%, including dividends. If you were weighing that decision back in November 2025, what did the mix of pipeline promise and looming risks really signal about taking that ride?
The move put Merck in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it.
The Two Merck Stories Investors Had To Weigh
The shares cost US$91.45 at the start of the period, and Merck sat between two clear storylines about where the value might lie.
The bullish script pointed to a Fair Value of US$102, a rough guide to what that scenario implied the stock could be worth if it played out, built on assumptions of 4.2% annual revenue growth and profit margins reaching 33.7% within three years.
The bearish view anchored on a Fair Value of US$82, tied to concerns about global pricing pressure and the eventual loss of exclusivity for KEYTRUDA.
What The Merck Evidence Actually Tested
The key test for Merck was whether pipeline progress could justify those higher Fair Value cases while profits were under pressure. Oncology approvals and late stage wins, from KEYTRUDA combinations to sacituzumab tirumotecan, supported the optimistic story about future cash engines. The latest quarterly filing pulled the other way. Revenue rose while net income and net margin fell, so profitability progress in the bullish script remained unproven. Overall, the evidence cut both ways.
The lesson is simple. When a thesis leans on future margin expansion, do not just watch sales or trial headlines. Track whether net income and reported net margin actually move toward the forecast levels in each new report.
What Merck’s Rally Already Prices In
Merck trades at US$147 today after a 62.8% gain over the past year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level and argues the recent climb already bakes in a confident read on the late stage pipeline.
To pay today’s price, you effectively assume Merck turns oncology combinations, vaccines and newer launches into a durable earnings bridge beyond KEYTRUDA. The question is how the concentration, safety and regulatory risks in this Narrative affect that assumption for you.
"Management’s plan to grow through the KEYTRUDA loss of exclusivity by relying on more than US$70b in non risk adjusted mid 2030s revenue from over 20 new human health products depends on many launches and label expansions still ahead, and any combination of regulatory delays, competitive pressure or safety issues similar to those seen in I DXd and remigromig could leave total human health revenue and earnings meaningfully short of those ambitions."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Looking One Step Beyond Merck
Merck pulls you toward oncology, vaccines and complex chronic care. Your watchlist does not have to stop there.
The same aging and obesity trends that frame Merck’s story also shape demand for cardiometabolic drugs that tackle diabetes and weight together.
One large pharmaceutical group is leaning into that need, focusing on incretin medicines, oral options and combination therapies for tougher metabolic cases.
Its newer oncology, immunology and neuroscience projects add treatment lines that do not rely on a single obesity product.
If those parallel bets keep reshaping chronic care, this second giant could influence your longer term healthcare exposure.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 16% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com